OXiGENE To Present At BIO CEO And Investor Conference On February 12, 2008

Boston, Sweden, Feb 5, 2008 - (ABN Newswire) - WALTHAM, Mass.--(BUSINESS WIRE) - February 5, 2008--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that President and CEO Richard Chin, M.D., will present a corporate overview and update at the BIO CEO and Investor Conference on Tuesday, February 12, at 10:15 a.m. EST (7:15 a.m. PST), in the Waldorf-Astoria hotel's Norse Suite in New York City, NY.

A live and archived webcast of the presentation can be accessed for 30 days following the presentation under the Investor Center tab at www.oxigene.com.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients. # # #

Investor and Media Contact: Michelle Edwards, Investor Relations medwards@oxigene.com 415-315-9413



LINK: http://hugin.info/1164/R/1188229/238570.pdf

Copyright © Hugin AS 2008. All rights reserved.

Oxigene

http://www.oxigene.com

ISIN: US6918281071

Stock Identifier: XOME.OXGN

US: OXGN